NEOGENOMICS, INC. (NASDAQ:NEO) Files An 8-K Results of Operations and Financial Condition

Item 2.02.

On February 22, 2017, NeoGenomics, Inc. (the Company) hosted an
earnings call to discuss its results for its fourth fiscal
quarter of 2016 and full year ended December 31, 2016.The
transcript of the earnings call is furnished herewith as Exhibit
99.1 and is incorporated herein by reference.

This information shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, and it shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.

This Form 8-K and the transcript furnished herewith may include
statements that are forward-looking statements within the meaning
of the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. All statements herein or in the
exhibit hereto other than statements of historical fact are
“forward-looking statements, which involve risks and
uncertainties and are only predictions. Actual events or results
may differ materially from those contemplated by forward-looking
statements for a variety of reasons, including those described in
the transcript furnished herewith. There are risks that the
Company faces that could cause actual results to be materially
different from those that may be set forth in forward-looking
statements made by the Company. There also may be additional
risks that the Company does not presently know or that it
currently believes are immaterial which could also impair its
business and results of operations. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of their dates. The Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. Additional information regarding factors that could
materially affect results and the accuracy of the forward-looking
statements contained herein, or the transcript furnished
herewith, may be found in the transcript.

About NEOGENOMICS, INC. (NASDAQ:NEO)

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.

NEOGENOMICS, INC. (NASDAQ:NEO) Recent Trading Information

NEOGENOMICS, INC. (NASDAQ:NEO) closed its last trading session down -0.16 at 8.03 with 753,751 shares trading hands.